AOD-9604 / MOTS-c / Tesamorelin Blend

AOD-9604 / MOTS-c / Tesamorelin Blend combines three peptides studied through distinct pathways related to fat metabolism: AOD-9604, a modified fragment of human growth hormone studied for direct lipolytic activity; MOTS-c, a mitochondrial-derived peptide studied for effects on insulin sensitivity and exercise-like metabolic adaptation; and Tesamorelin, a growth hormone-releasing hormone (GHRH) analog approved in some regions specifically for reducing visceral fat in HIV-associated lipodystrophy. The rationale for combining them is to address fat metabolism from three angles at once, direct lipolysis, cellular energy regulation, and the GH/IGF-1 axis, rather than relying on a single mechanism. Tesamorelin is the only component with formal clinical trial and regulatory history; AOD-9604 and MOTS-c remain investigational. No published research has evaluated the three peptides administered together, so anticipated additive effects are inferred rather than demonstrated. Reported benefits include tesamorelin has clinical trial evidence for visceral fat reduction in a specific approved indication, aod-9604 is studied for direct lipolytic activity without the broader gh-axis stimulation associated with growth hormone secretagogues, mots-c is studied for insulin sensitivity and exercise-mimetic metabolic effects.

Reported ranges run 1-3 mg. A low protocol is 1 mg once daily, and a high protocol is 3 mg once daily. This is reference information, not a dosing recommendation.

The three components have differing, generally short half-lives: tesamorelin's is on the order of 25-40 minutes, AOD-9604's is similarly brief, and MOTS-c's has been estimated at a few hours in early studies, which is why daily dosing is typically described for this blend.. That is what sets the dosing frequency, and it is why the timing guidance is morning, before exercise.

Subcutaneous: into fat, under the skin. All three components are individually studied via subcutaneous injection, consistent with this blend's administration.

8-12 weeks on, followed by 4 weeks off. Modeled on cycling patterns described for tesamorelin and AOD-9604 individually. Periodic monitoring of fasting glucose and IGF-1 is commonly suggested given tesamorelin's known effects on the GH axis.

Reported side effects include injection site reactions, fluid retention, joint pain, or paresthesia, effects documented with tesamorelin in clinical trials, changes in blood glucose or insulin sensitivity, headache, combined effects of the three peptides administered together have not been formally studied. Evidence level for this compound is emerging research.